NO175602C - Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid - Google Patents

Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid

Info

Publication number
NO175602C
NO175602C NO862313A NO862313A NO175602C NO 175602 C NO175602 C NO 175602C NO 862313 A NO862313 A NO 862313A NO 862313 A NO862313 A NO 862313A NO 175602 C NO175602 C NO 175602C
Authority
NO
Norway
Prior art keywords
preparation
interferon polypeptide
hybrid interferon
interferons
novel hybrid
Prior art date
Application number
NO862313A
Other languages
English (en)
Norwegian (no)
Other versions
NO175602B (no
NO862313L (no
NO862313D0 (no
Inventor
Francois Meyer
Albert Hinnen
Andreas Meister
Markus Gerhard Grutter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO862313D0 publication Critical patent/NO862313D0/no
Publication of NO862313L publication Critical patent/NO862313L/no
Publication of NO175602B publication Critical patent/NO175602B/no
Publication of NO175602C publication Critical patent/NO175602C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO862313A 1985-06-11 1986-06-10 Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid NO175602C (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon

Publications (4)

Publication Number Publication Date
NO862313D0 NO862313D0 (no) 1986-06-10
NO862313L NO862313L (no) 1986-12-12
NO175602B NO175602B (no) 1994-07-25
NO175602C true NO175602C (no) 1994-11-02

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862313A NO175602C (no) 1985-06-11 1986-06-10 Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid

Country Status (20)

Country Link
US (2) US4885166A (de)
EP (1) EP0205404B1 (de)
JP (2) JPH0655759B2 (de)
KR (1) KR920002267B1 (de)
AT (1) ATE78262T1 (de)
AU (1) AU598196B2 (de)
CA (1) CA1285507C (de)
CY (1) CY1842A (de)
DE (1) DE3685996T2 (de)
DK (1) DK168794B1 (de)
FI (1) FI90983C (de)
GR (1) GR861497B (de)
HK (1) HK99895A (de)
HU (1) HU203255B (de)
IE (1) IE57865B1 (de)
IL (1) IL79085A (de)
NO (1) NO175602C (de)
NZ (1) NZ216485A (de)
PT (1) PT82736B (de)
SG (1) SG25195G (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
DK0546124T4 (da) * 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DE69222013T2 (de) * 1991-12-16 1998-01-29 Ciba Geigy Ag Endoplasmatisches Retikulum-ständige rekombinante dibasische Endoprotease und deren Verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69323131T2 (de) * 1992-03-10 1999-09-16 La Jolla Cancer Research Foundation, La Jolla Rekombinierte alkalische phosphatase aus kälberdarm
TW218846B (de) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (de) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5981227A (en) 1995-02-09 1999-11-09 Movartis Ag Process for the production of proteins
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1565205A4 (de) * 2002-11-18 2006-07-05 Maxygen Inc Interferon-alpha polypeptide und konjugate
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2005245918A1 (en) 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2007014524A (es) * 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
SI2041259T1 (sl) * 2006-07-14 2016-04-29 Dpx Holdings B.V. Izboljšan postopek kultiviranja celic
EP2049081B1 (de) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotische freisetzungssysteme und kolbenanordnungen
EP2077858A4 (de) 2006-12-06 2011-07-20 Medimmune Llc Interferon alpha-induzierte pharmakodynamische marker
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
MX2009011870A (es) * 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
EP2076590A4 (de) 2007-05-03 2011-06-01 Medimmune Llc Auto-antikörper-marker für autoimmunerkrankungen
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
PT2219452E (pt) 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
SG188147A1 (en) 2008-02-08 2013-03-28 Medimmune Llc Disease markers and uses thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012229104B2 (en) 2011-03-15 2017-03-16 Biogen Ma Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3924383A1 (de) 2019-02-15 2021-12-22 Astrazeneca AB Interferon-vermittelte störungen vom typ i
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54096B1 (en) * 1980-01-08 1989-06-21 Biogen Nv Dn sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
EP0173935A1 (de) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid-Lymphoblastoid-Leukozyten-Humaninterferone

Also Published As

Publication number Publication date
FI90983B (fi) 1994-01-14
CY1842A (en) 1996-03-08
HUT41846A (en) 1987-05-28
JPH0736757B2 (ja) 1995-04-26
GR861497B (en) 1986-10-10
JPS626000A (ja) 1987-01-12
NZ216485A (en) 1991-06-25
KR920002267B1 (ko) 1992-03-20
DK272986A (da) 1986-12-12
US4885166A (en) 1989-12-05
FI862461A0 (fi) 1986-06-09
DK272986D0 (da) 1986-06-10
NO175602B (no) 1994-07-25
DK168794B1 (da) 1994-06-13
ATE78262T1 (de) 1992-08-15
KR870000427A (ko) 1987-02-18
PT82736B (pt) 1988-12-15
NO862313L (no) 1986-12-12
AU5849986A (en) 1986-12-18
HU203255B (en) 1991-06-28
IE861542L (en) 1986-12-11
IE57865B1 (en) 1993-05-05
EP0205404A2 (de) 1986-12-17
CA1285507C (en) 1991-07-02
US5071761A (en) 1991-12-10
FI90983C (fi) 1994-04-25
NO862313D0 (no) 1986-06-10
FI862461L (fi) 1986-12-12
DE3685996D1 (de) 1992-08-20
SG25195G (en) 1995-08-18
AU598196B2 (en) 1990-06-21
IL79085A (en) 1992-03-29
JPH0655759B2 (ja) 1994-07-27
EP0205404B1 (de) 1992-07-15
EP0205404A3 (en) 1987-10-21
HK99895A (en) 1995-06-30
JPH05308973A (ja) 1993-11-22
IL79085A0 (en) 1986-09-30
DE3685996T2 (de) 1993-01-14
PT82736A (en) 1986-07-01

Similar Documents

Publication Publication Date Title
NO175602C (no) Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid
ES2119735T3 (es) Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones.
NO872988L (no) Pattedyr-interleukin-4.
AU2964489A (en) Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
FI874287A7 (fi) Uudet lymfokiinipeptidit.
ES8601237A1 (es) Procedimiento para preparar dnas y dnas recombinantes
NZ212937A (en) Omega interferons: production by recombinant dna processes; pharmaceutical compositions
EP0315637A4 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben.
NZ228105A (en) Antihypertensive hyperimmune milk, its production and medicaments therefrom
DE3169559D1 (en) Lymphoblastoid cell lines capable of continuously and spontaneously producing interferon, process for preparing the same, and process for the human interferon production by the same
AU1702488A (en) Polypeptides useful in diagnosis of coccidia infection and recombinant-dna methods for manufacturing same
NO166727C (no) Fremgangsmaate for fremstilling av rekombinant alfa-interferon
DE3574145D1 (en) Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
IT8348536A0 (it) Procedimento per la produzione di interferon
FI874273A0 (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
GB2168355B (en) Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
IL92316A0 (en) Recombinant interleukin-2 hybrid proteins,their production and pharmaceutical compositions containing them
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
ATE102997T1 (de) Thymosin und tnf-kodierende dna.

Legal Events

Date Code Title Description
MK1K Patent expired